Form 4: SpyGlass Pharma Insider Boosts Stake to 6M Shares

Edward T. Mathers, a director and 10% owner of SpyGlass Pharma, Inc., significantly increased his indirect beneficial ownership to over 6 million common shares through conversions and a direct purchase.

Summary

• Edward T. Mathers, a Director and 10% Owner of SpyGlass Pharma, Inc. (SGP), reported significant changes in his beneficial ownership.
• Mathers' indirect beneficial ownership of common stock increased to a total of 6,035,038 shares following a series of transactions.
• This includes the automatic conversion of 1,619,240 Series B, 1,370,168 Series C-1, 1,370,168 Series C-2, and 737,962 Series D Preferred Stock into common stock on a one-for-one basis.
• Additionally, Mathers indirectly acquired 937,500 shares of common stock at a price of $16 per share.
• All preferred stock conversions occurred prior to the closing of the Issuer's initial public offering (IPO) on February 9, 2026.
• Mathers' beneficial ownership is indirect, held through New Enterprise Associates 17, L.P. (NEA 17), where he is a manager of the general partner. He disclaims beneficial ownership for any portion where he has no pecuniary interest.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as a director and significant owner has substantially increased their stake, including a direct purchase, indicating high confidence in SpyGlass Pharma's prospects, especially around its IPO.

Positives

• A director and 10% owner significantly increased their indirect beneficial ownership, signaling confidence in the company's future.
• The conversion of various series of preferred stock into common stock prior to the IPO simplifies the capital structure and indicates a move towards public trading.
• A direct purchase of 937,500 common shares at $16 per share demonstrates a tangible investment by an insider.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company, focusing solely on the insider's transaction details.

Industry Context

StockSavvy.ai notes that insider transactions, particularly purchases by directors and significant owners, are often viewed by the market as a positive indicator of management's confidence in the company's future prospects. This activity by a director of SpyGlass Pharma, Inc. around its IPO date suggests strong internal belief in the company's valuation and growth trajectory, which can differentiate it from peers in the biotechnology or pharmaceutical sector that might not see similar insider commitment post-IPO.

Related Party Transactions

• Edward T. Mathers' beneficial ownership is indirect, held through New Enterprise Associates 17, L.P. (NEA 17), where he is a manager of the general partner of NEA Partners 17, L.P., which is the sole general partner of NEA 17. This structure is common for venture capital investments.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of confidence from a director and significant investor, potentially boosting investor sentiment.
• The conversion of preferred stock to common stock simplifies the capital structure, which can be beneficial for all common shareholders.

Key Dates

Keywords

SpyGlass Pharma, SGP, Insider Trading, Form 4, Beneficial Ownership, Common Stock, Preferred Stock Conversion, IPO, Edward T. Mathers, New Enterprise Associates